Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Spartalizumab (Primary) ; Dabrafenib; Trametinib
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Acronyms COMBI-i
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 16 Apr 2024 This trial has been completed in Greece according to European Clinical Trials Database record.
- 10 Apr 2024 This trial has been completed in Portugal according to European Clinical Trials Database record.
- 08 Apr 2024 Planned End Date changed from 29 Mar 2024 to 2 Aug 2024.